Articles tagged with Cancer Patients
The phase III trials indicate that anamorelin is safe and well-tolerated in treating symptoms of advanced non-small cell lung cancer anorexia-cachexia. Patients experienced improvements in lean body mass, body weight, and patient symptoms/concerns regarding appetite over 12 weeks.
A substantial proportion of potential subjects are reflexively excluded from lung cancer clinical trials due to prior cancer. The exclusion criterion was applied in more than two-thirds of trials in which survival was not the primary endpoint, resulting in up to 18% exclusion rate.
A simple blood test could be used to identify patients at risk of cancer due to high levels of calcium in the blood. Researchers found that in men, even mild hypercalcaemia conferred a risk of cancer in one year of 11.5%, while in women, the corresponding figure was 4.1%. The study suggests that hyperparathyroidism may be responsible f...
Researchers at USC Keck Medicine have discovered a dual purpose of the cancer drug decitabine in regulating gene expression. The study found that the drug not only reactivated tumor suppressor genes but also down-regulated overexpressed oncogenes, which are responsible for cancer progression. This new mechanism may provide additional t...
The European Organisation for Research and Treatment of Cancer (EORTC) will showcase its latest cancer research findings at the ESMO 2014 Congress. The conference will feature various sessions, including a joint symposium on clinical trials and posters focused on immunotherapy and gastrointestinal tumors.
The 1st EORTC Cancer Survivorship Summit has reported improved survival rates for patients with cancer, while also highlighting the need to address late adverse treatment effects. The summit addressed various topics including second malignancies, cardiovascular disease, and psycho-social problems following cancer treatment.
A new study of 1074 cancer patients who smoke found that e-cigarette use did not help with quitting traditional cigarettes. The study, published in the American Cancer Society journal, found a three-fold increase in e-cigarette use among smokers over two years.
A new research study reveals that many patients with advanced, incurable cancer do not receive palliative care, despite the presence of designated centres promoting integrated oncology and care. The study found significant gaps in palliative care delivery, highlighting the need for increased budget allocation.
Researchers found that combining targeted radiation therapy (SBRT) with the drug cetuximab improved treatment outcomes for patients with recurrent squamous cell carcinoma of the head and neck. The study showed a significant reduction in severe toxicity, allowing patients to complete treatments faster.
A genetic discovery has led to a highly accurate test for aggressive prostate cancer recurrence, identifying new avenues for treatment. The test is 91 percent accurate and could potentially lead to a cure through genetic therapy.
Researchers found alterations in genes BAP1, KDM6A, and others contributing to bladder cancer development. These findings suggest potential therapeutic targets for specific subtypes of the disease.
A study published in Nicotine & Tobacco Research suggests that a mix of gain- and loss-framed messages may work best to help convince smokers to quit. The research found that
A new radiotherapy strategy for treating advanced small-cell lung cancer significantly prolongs long-term survival and reduces cancer recurrence in the chest. The study found that patients treated with thoracic radiation therapy had a 50% lower risk of cancer recurrence compared to those who did not receive it.
A new Penn Medicine study reveals that certain patient characteristics, such as being male, married, and younger than 65, may be associated with shorter hospice stays. The study also found that patients with blood cancers and Medicaid or uninsured status tend to enroll in hospice earlier in their illness
Georgetown Lombardi Comprehensive Cancer Center has received a five-year, $11.25 million P30 Cancer Center Support Grant to continue its laboratory science, clinical research and population-based programs. The NCI designation reaffirms the high quality work of dedicated cancer researchers at Georgetown.
A phase Ib clinical trial found that olaparib tablets were safe and effective in heavily pretreated ovarian cancer patients, particularly those with BRCA mutations. The treatment regimen provided a response rate of 66 percent and no grade 4 toxicities, making it a promising option for improving cure rates and quality of life.
A study of German cancer centers found that many patients do not receive a dignified death due to inadequate staff training and facilities. Palliative care staff reported better conditions than other hospital wards, with 95% indicating that patients die with dignity.
Researchers found that the protein RBM4, crucial to gene splicing, is drastically decreased in multiple forms of human cancer, including lung and breast cancers. This discovery offers a new route toward therapies targeting altered genetic pathways that allow cancer cells to proliferate and spread.
A recent MD Anderson study found that socio-economic barriers continue to preclude women from receiving breast-conserving therapy, despite overall rates improving. The study identified disparities related to insurance, income, and education, with significant disparities still existing in areas outside the medical field.
Researchers identified rare stem cells in testis that produce PAX7, helping give rise to new sperm cells and potentially restoring fertility. These stem cells were found to be highly resistant to cancer treatments, suggesting they may play a key role in recovering fertility.
Scientists at MD Anderson Cancer Center have discovered genetic mutations in a subset of endometrial cancer patients that are associated with a more lethal form of the disease. The identification of these mutations could lead to the development of targeted treatments and improved patient outcomes.
A team of researchers has developed a mathematical model for epigenetic silencing, which reveals how DNA sequences are silenced in cancer cells. The model explains how histone and DNA methylation work together to regulate gene expression, and could lead to new strategies for preventing cancer development.
A Mayo Clinic study found that patients with poor quality of life before cancer surgery are nearly three times more likely to experience serious postoperative complications. Addressing these quality-of-life issues may reduce stress, speed recoveries and save healthcare costs.
Researchers are urging experts to study the functions of 'assemblages' - cloud-like protein formations that may hold clues to new treatments for diseases like Ewing sarcoma. These assemblages are made up of intrinsically disordered proteins that can trap and interact with other biological molecules.
Researchers found that high out-out assortativity in transcription factor networks contributes to robustness, with similar numbers of outgoing connections among connected TFs. This signature is a predictor of robustness, with an above-average number of connected TFs exhibiting this property.
The Herbert Irving Comprehensive Cancer Center has been awarded an $18 million grant to continue its groundbreaking research and provide high-quality patient care. The center, led by Dr. Stephen Emerson, is recognized as one of the top cancer centers in New York City and the country.
A new integrated treatment programme is more effective at reducing depression and improving quality of life than current care for depressed cancer patients. The programme, called 'Depression Care for People with Cancer', includes both antidepressants and psychological therapy.
Kids Konnected and the Breast and Gyn Health Project in California will each receive $8,500 awards to support their work assisting cancer patients and their families. The organizations will also be featured at ASTRO's Annual Meeting in San Francisco.
Patients with advanced laryngeal cancer who underwent surgery had significantly better disease-specific and overall survival rates compared to those treated with nonsurgical chemoradiation. The study analyzed data from over 5,000 patients diagnosed between 1992 and 2009.
A study at Huntsman Cancer Institute found compound mutations containing T315I confer complete resistance to all available TKIs, highlighting the need for new treatment options. Researchers have created a dataset that can help clinicians decide which drug will be most effective for each mutation combination.
Researchers have identified a biomarker, STAT3 protein, strongly associated with basal-like breast cancer, a highly aggressive and resistant carcinoma. This finding suggests a potential target for new therapeutics designed to treat this deadly cancer subtype.
The VCU Massey Cancer Center has been awarded a $4.4 million grant to establish a statewide cancer clinical trials network in Virginia, focusing on minority access and addressing cancer disparities. The network will provide cancer patients with opportunities to participate in clinical trials in their local communities.
Researchers at VCU Massey Cancer Center found that protein AEG-1 interferes with retinoic acid's ability to treat leukemia and liver cancer, highlighting a potential target for new therapies. The study's results could impact the treatment of countless cancer patients by enabling doctors to screen for AEG-1 expression levels.
A large study published in European Urology has found that needle-guided tumor destruction procedures, such as partial nephrectomy and radiofrequency ablation, offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors.
Beaumont Health System receives a five-year National Cancer Institute Community Oncology Research Program grant to conduct cancer research and clinical trials in Michigan communities. The program aims to reduce cancer disparities and improve patient outcomes.
The LSU Health Sciences Center New Orleans has received a $5.6 million NCI grant to build a regional cancer clinical trials network, focusing on minority and underserved patients who die at higher rates from cancer. The program aims to provide access to state-of-the-art treatments and create jobs in the biomedical workforce.
A recent study published in the Journal of Clinical Oncology suggests that patient navigation can lead to better breast cancer care for high-risk populations, including minority women. Researchers found that patients assisted by trained navigators were more likely to start recommended treatments, such as hormonal therapy.
Researchers have found a link between tumor suppressor mutations and missing segments of genetic material in squamous cell head and neck cancers. The study suggests that treating tumors with both markers may intensify treatment, while those with only one marker may benefit from de-intensified treatment.
Researchers have developed a first-of-its-kind molecular test kit that can predict treatment and survival outcomes in kidney cancer patients based on their tumor profile. The assay was able to distinguish patients into groups with different survival and treatment outcomes, allowing for more educated choices in treatment options.
Researchers at CWRU aim to boost cancer trial participation by educating oncology nurses. The $1.6 million NCI grant-funded program will test a web-based educational tool, Oncology Nurse IMPACT, to address barriers and increase discussions about clinical trials between nurses and patients.
A study published in the British Journal of Cancer found that bladder cancer patients with high levels of the protein HIF-1α are more likely to benefit from a treatment called CON, which makes radiotherapy more effective. High levels of the protein were linked to better survival rates when patients had radiotherapy and CON.
Researchers at the University of Pennsylvania have developed a new technique to help surgeons see the entire tumor during surgery, increasing the likelihood of a positive outcome. The approach uses an injectable dye that accumulates in cancerous tissues, allowing surgeons to remove the entire malignancy.
Researchers have found an irreversible inhibitor, SML-8-73-1, that selectively and irreversibly interferes with the activity of mutated KRAS genes. This breakthrough has significant potential to target cancer cells and improve treatment outcomes for patients with lung, pancreas, and colon cancers.
Researchers have devised a simple blood test that can diagnose cancer with high accuracy, saving time and preventing costly procedures. The Lymphocyte Genome Sensitivity (LGS) test measures DNA damage caused by ultraviolet light, distinguishing between cancerous and healthy cells.
A molecular testing panel developed at UPMC has improved the chances of correct initial surgery for thyroid cancer patients by 30 percent. The test, available at the UPMC/UPCI Multidisciplinary Thyroid Center, bypasses initial surgeries and allows for more efficient removal of cancerous tissue.
Patients with diabetes are at a higher risk for developing head and neck cancers, which account for about 6% of all cancer cases globally. A study found that the incidence of HNC was 1.47 times higher in diabetic patients compared to those without diabetes.
Researchers tested genetically engineered virus alongside isolated limb perfusion chemotherapy, finding it more effective in rats than either treatment alone. The combination slowed tumour growth and prolonged survival by 50%, offering hope for avoiding amputation and improving quality of life.
Patients with advanced cancer can experience improvement in fatigue, physical endurance, and mood through rehabilitation programs combining exercise and nutritional counselling. Palliative care services should incorporate these elements to enhance patient outcomes.
Researchers at Queen's University have made a significant breakthrough that may benefit patients with bowel cancer. The team discovered how two genes cause bowel cancer cells to become resistant to treatments, leading to the development of a new approach to target these genes in aggressive forms of the disease.
Huntsman Cancer Institute will become a key partner in the National Clinical Trials Network, providing access to clinical trials for patients across the Intermountain West region. The institute's unique research assets, including the Utah Population Database and Center for Quantitative Imaging Excellence, will enable multi-institutiona...
Research reveals that white fat transforming into brown fat may stimulate weight gain and muscle strength in cancer patients suffering from cachexia. The browning process is triggered by inflammation, and anti-inflammatory therapies show promise in alleviating the condition.
A new study by Henry Ford Health found that robot-assisted surgery can control prostate cancer for up to 10 years. The research followed 483 men who had not spread cancer beyond the prostate and received robot-assisted radical prostatectomy (RARP) as their first treatment, with 98.8% surviving the disease for 10 years.
Certain cancers have a characteristic age at which they occur, and their incidence decreases beyond that age. This 'developmental origin of disease hypothesis' suggests many cancers originate early in life, possibly before birth.
Two studies suggest that primary androgen deprivation therapy (ADT) for low-risk prostate cancer is not associated with improved survival rates. Alternative treatments may be more effective for patients, but must consider the potential adverse effects and costs of ADT.
A large population-based study of European adults with blood cancers found that regional differences in treatment and care quality contribute to varying survival rates. The study analyzed data from 30 cancer registries covering all patients diagnosed in 20 European countries between 1997 and 2008.
A new study has identified a molecular cause of cachexia and suggests a potential treatment using an anti-PTHrP antibody. The research found that blocking the effects of PTHrP can prevent wasting and improve muscle mass in mice with lung tumors.
The U.S. Department of Health and Human Services has awarded a three-year, $4.7 million grant to University Hospitals Case Medical Center Seidman Cancer Center to test a new national model aimed at improving care for adult cancer patients with late-stage disease. The project will enhance care through individualized interventions, inclu...
Researchers have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, expanding therapeutic targets and potentially identifying treatable mutations. The study found that 75% of patients with lung adenocarcinoma have actionable mutations that can be treated with existing or under-development drugs.
A study by UT Southwestern found a five-fold increase in cancer patients using MyChart from 2009 to 2015, with those over 60 making up the majority of frequent users. The technology's convenience and ease of use contribute to its widespread adoption among this demographic.
A new study by the University of Edinburgh has found that bowel cancer patients with high levels of vitamin D in their blood are more likely to survive the disease. Patients with the highest levels of vitamin D have half the risk of dying compared to those with the lowest levels, according to the research.